Clinical momentum Olvi-Vec is in a Phase 3 registrational trial for platinum-resistant ovarian cancer with additional systemic programs in NSCLC and recurrent SCLC and ovarian cancer, indicating broad late-stage potential for collaboration or strategic partnerships in immuno-oncology.

Financial runway Company reports cash and equivalents of approximately $26 million as of March 31, 2026, with projected funding to support operations into early 2027, suggesting a need for partnered funding avenues, milestone-driven deals, or co-development partnerships to extend runway.

Evidence of efficacy Translational analyses and interim Phase 2/3 data show immune activation and chemotherapy sensitization with Olvi-Vec, plus signals of activity in SCLC and NSCLC, creating opportunities to discuss combination trials and expansion into adjacent solid tumor indications.

Market readiness Upcoming topline data from the OnPrime/GOG-3076 ovarian cancer registrational trial expected in 2H26 presents a clear inflection point for licensing, collaboration, or co-promotion discussions with larger oncology partners.

Strategic outreach Active investor and analyst engagement, recent equity offering, and public communications indicate a favorable window for business development conversations around strategic investments, partnerships, and potential out-licensing of Olvi-Vec and related platform opportunities.